Publications

Selected Publications

Hambardzumyan K, Saevarsdottir S, Forslind K, Petersson IF, Wallman JK, Ernestam S, Bolce RJ, van Vollenhoven RF. A multi-biomarker disease activity score and the choice of second-line therapy in early rheumatoid arthritis after methotrexate failure.. Arthritis Rheumatol. 2016 Dec 19. doi: 10.1002/art.40019.

Curtis JR, Wright GC, Strand V, Davis CS, Hitraya E, Sasso EH. Reanalysis of the multi-biomarker disease activity score for assessing disease activity in the AMPLEstudy: Comment on the article by Fleischmann et al. Arthritis Rheumatol. 2016 Nov 3. doi: 10.1002/art.39981.

Hambardzumyan K, Bolce R, Saevarsdottir S, Forslind K, Wallman J, Cruickshank S, Sasso E, Chernoff D, van Vollenhoven R. Association of a multi-biomarker disease activity score at multiple time-points with radiographic progression in rheumatoid arthritis: results from the SWEFOT trial. RMD Open 2016. doi:10.1136/rmdopen-2015-
000197.

Hirata S, Li W, Kubo S, Fukuyo S, Mizuno Y, Hanami K, Sawamukai N, Yamaoka K, Saito K, Defranoux N, Tanaka Y. Association of the multi-biomarker disease activity score with joint destruction in patients with rheumatoid arthritis receiving tumor necrosis factor-alpha inhibitor treatment in clinical practice. Modern Rheumatology 2016. DOI:10.3109/14397595.2016.1153449.

Hirata S, Defranoux N, Hanami K, Yamaoka K, Tanaka Y. A multi-biomarker disease activity score for monitoring rheumatoid arthritis. Current Biomarker Findings 2015:5 69-78. doi:10.2147/CBF.S46912.

Li W, Sasso EH, van der Helm-van Mil AHM, Huizinga TWJ. Relationship of multi-biomarker disease activity score and other risk factors with radiographic progression in an observational study of patients with rheumatoid arthritis. Rheumatology (Oxford) 2015. doi:10.1093/rheumatology/kev341.

Lee YC, Hackett J, Frits M, Iannaccone CK, Shadick NA, Weinblatt ME, Segurado OG, Sasso EH. Multibiomarker disease activity score and C-reactive protein in a cross-sectional observational study of patients with rheumatoid arthritis with and without concomitant fibromyalgia.. Rheumatology (Oxford). 2016 Apr;55(4):640-8. doi: 10.1093/rheumatology/kev388.

Rech J, Hueber AJ, Finzel S, Englbrecht M, Haschka J, Manger B, Kleyer A, Reiser M, Cobra JF, Figueiredo C, Tony HP, Kleinert S, Wendler J, Schuch F, Ronneberger M, Feuchtenberger M, Fleck M, Manger K, Ochs W, Schmitt-Haendle M, Lorenz HM, Nuesslein H, Alten R, Henes J, Krueger K, Schett G. Prediction of disease relapses by multibiomarker disease activity and autoantibody status in patients with rheumatoid arthritis on tapering DMARD treatment.. Ann Rheum Dis. 2016 Sep;75(9):1637-44. doi: 10.1136/annrheumdis-2015-207900.

van Vollenhoven RF, Bolce R, Hambardzumyan K, Saevarsdottir S, Forslind K, Petersson I, Sasso EH, Hwang CC, Segurado OG, Geborek P. The use of a multi-biomarker disease activity score as an inclusion criterion in rheumatoid arthritis clinical trials may enhance patient recruitment. Arthritis & Rheumatology 2015. DOI: 10.1002/art.39274

Hirata S, Li W, Defranoux N, Cavet G, Bolce R, Yamaoka K, Saito K, Tanaka Y. A multi-biomarker disease activity score tracks clinical response consistently in patients with rheumatoid arthritis treated with different anti-tumor necrosis factor therapies: A retrospective observational study. Modern Rheumatology 2014. doi:10.3109/14397595.2014.958893

Hambardzumyan K, Bolce R, Saevarsdottir S, Cruickshank SE, Sasso EH, Chernoff D, Forslind K, Petersson I, Geborek P, van Vollenhoven RF. Pre-treatment multi-biomarker disease activity score and radiographic progression in early RA: results from the SWEFOT trial. Ann Rheum Dis 2014. doi:10.1136/annrheumdis-2013-204986

van der Helm-van Mil AHM, Knevel R, Cavet G, Huizinga TWJ, and Haney DJ. An Evaluation of Molecular and Clinical Remission in Rheumatoid Arthritis by Assessing Radiographic Progression. Rheumatology (Oxford). 2013. doi:10.1093/rheumatology/kes378.

Segurado O, Sasso E. Vectra DA for the objective measurement of disease activity in patients with rheumatoid arthritis. Clin Exp Rheumatol 2014; 32 (Suppl. 85): S29-S34.

Markusse IM, Dirven L, van den Broek M, Bijkerk C, Huub Han K, Karel Ronday H, Bolce R, Sasso EH, Kerstens PJSM, Lems WF, Huizinga TWJ, Allaart CF. A Multibiomarker Disease Activity Score for Rheumatoid Arthritis Predicts Radiographic Joint Damage in the BeSt Study. The Journal of Rheumatology131412. doi:10.3899/jrheum.131412

Hirata S, Dirven L, Shen Y, Centola M, Cavet G, Lems WF, Tanaka Y, Huizinga TWJ, Allaart CF. A multi-biomarker score measures rheumatoid arthritis disease activity in the BeSt study. Rheumatology (Oxford) 2013, doi: 10.1093/rheumatology/kes362.

Curtis JR, van der Helm-van Mil AH, Knevel R, Huizinga TW, Haney DJ, Shen Y, Ramanujan S, Cavet G, Centola M, Hesterberg LK, Chernoff D, Ford K, Shadick NA, Hamburger M, Fleischmann R, Keystone E, Weinblatt ME. Validation of a novel multi-biomarker test to assess rheumatoid arthritis disease activity. Arthritis Care & Research. 2012; 64 (12):1794–1803.

Li W, Sasso E, Emerling D, Cavet G, Ford K. Impact of a multi-biomarker disease activity test on rheumatoid arthritis treatment decisions and therapy use. Current Medical Research & Opinion. 2013; 29(1): 85-92.

Michaud K, Strand V, Shadick N, Degtiar I, Ford K, Michalopoulos S, Hornberger J. Outcomes and costs of incorporating a multibiomarker disease activity test in the management of patients with rheumatoid arthritis. Rheumatology (Oxford) 2015, doi:10.1093/rheumatology/kev023.

Reiss WG, Devenport JN, Low JM, et al. Interpreting the multi-biomarker disease activity score in the context of tocilizumab treatment for patients with rheumatoid arthritis. Rheumatology International. 2015 DOI:10.1007/s00296-015-3285-2

Bakker MF, Cavet G, Jacobs JWG, Bijlsma JWJ, Haney D, Shen Y, Hesterberg L, Smith D, Centola M, van Roon JAG, Lafeber FPJG, Welsing PMJ. Performance of a multi-biomarker score measuring rheumatoid arthritis disease activity in the CAMERA tight control study. Ann Rheum Dis. 2012; doi:10.1136/annrheumdis-2011-200963

Burmester G, Weinblatt ME, McInnes IB, Porter D, Barbarash O, Vatutin M, et al. Efficacy and safety of mavrilimumab in subjects with rheumatoid arthritis. Ann Rheum Dis. 2012; doi:10.1136/annrheumdis-2012-202450.

Centola M, Cavet G, Shen Y, Ramanujan S, Knowlton N, Swan K, Turner M, Sutton C, Smith D, Haney D, Chernoff D, Hesterberg L, Carulli J, Taylor P, Shadick N, Weinblatt M, Curtis J. Development of a Multi-Biomarker Disease Activity Test for Rheumatoid Arthritis. PLOS ONE 2013 Apr 9;8(4):e60635. doi:10.1371/journal.pone.0060635.

Eastman PS, Manning WC, Qureshi F, Haney D, Cavet G, Alexander C, Hesterberg LK. Characterization of a multiplex, 12-biomarker test for rheumatoid arthritis. Journal of Pharmaceutical and Biomedical Analysis, epub, June 5, 2012.

Zhao X, Qureshi F, Eastman PS, Manning W, Alexander C, Robinson W, Hesterberg L. Pre-analytical effects of blood sampling and handling in quantitative immunoassays for rheumatoid arthritis. Journal of Immunological Methods. 2012; 378: 72-80

Peabody JW, Strand V, Shimkhada R, Lee R, Chernoff D. Impact of Rheumatoid Arthritis Disease Activity Test on Clinical Practice. PLoS ONE 2013 (8)5: e63215

 

Selected Presentations

Additional Crescendo Bioscience research and publications can be found at www.crescendobio.com.

Ma M, Garrood T, Li W, Defranoux N, Kingsley G, Cope A, Scott D. Multi-Biomarker Disease Activity Score is Associated with Power Doppler Ultrasound in Patients with Rheumatoid Arthritis in Low Disease Activity State. Arthritis Rheum 2014;66 Suppl 11 :1300.

Schett G, Finzel S, Rech J, Sasso EH, Segurado OG. Residual Inflammatory Activity Assessed by a Multi-Biomarker Disease Activity Blood Test is Linked to Structural Damage in RA Patients in Low Disease Activity/Remission and Normal C-Reactive Protein Level. EULAR Congress 2014. Ann Rheum Dis 2014;73(Suppl2).

Ma MH, Garrood T, Li W, Defranoux N, Kingsley GH, Scott DL, Cope AP.  Multi-Biomarker Disease Activity (Vectra® DA Algorithm) Score is Associated With Power Doppler Ultrasound in Patients With Rheumatoid Arthritis in Low Disease Activity State: The Remira Cohort.  EULAR Congress 2014. Ann Rheum Dis 2014;73(Suppl2).

Hanami K, Hirata S, Tasaka H, Li W, Bolce R, Sasso EH, Defranoux NA, Yamaoka K, Saito K, Tanaka Y. Behavior of the Multi-Biomarker Disease Activity (Vectra® DA Algorithm) Score and Components in Patients with Rheumatoid Arthritis Treated with Tocilizumab. Poster FRI0066. EULAR Congress 2013

Ma MH, Li W, Defranoux N, Kingsley, GH, Scott DL, Cope, AP. A Multi-Biomarker Disease Activity (Vectra® DA Algorithm)Score and Components Are Associated with Sustained Clinical Remission in Rheumatoid Arthritis: the REMIRA Study; Poster FRI0075. EULAR Congress 2013

Li W, Hensvold AH, Saevarsdottir S, Defranoux NA, Klareskog L, Catrina AI. Characterization of the Multi-Biomarker Disease Activity (Vectra® DA Algorithm) Score in a Subgroup of Patients from the Epidemiological Investigation of Rheumatoid Arthritis (EIRA) Cohort Receiving Methotrexate. Poster SAT0033. EULAR Congress 2013

Haney DJ, Cavet G, Durez P, Alten R, Burmester GR, Tak PP, Catrina AI, Gaillez C, Bars ML, Connolly S, Townsend R. Correlation of a Multi-Biomarker Disease Activity Response Assessment to Disease Activity Score 28 (C-Reactive Protein) Response Assessment and OMERACT RAMRIS Scores in a Placebo-Controlled Rheumatoid Arthritis Clinical Trial with Abatacept (ASSET). Poster 2159. ACR 2012 Annual Scientific Meeting, Washington DC.

Biljsma JWJ, Verhoef-Jurgens M, Bakker M, Jacobs JWG, Lafeber FPJ, Welsing PMJ, Cavet G, Chernoff D, Li W, Sasso EH, Haney DJ. Response to Methotrexate Plus Prednisone in CAMERA II Using a Multi-Biomarker Disease Activity (Vectra™ DA) Test and DAS28ESR. Poster 2125. ACR 2012 Annual Scientific Meeting, Washington DC.

Tanaka Y, Hanami K, Tasaka H, Fukuyo S, Haney DJ, Bolce R, Debranoux N, Cavet G, Chernoff D, Yamaoka K, Saito K, Hirata S. A Multi-Biomarker Disease Activity Score (Vectra™ DA algorithm score) Reflects Clinical Disease Activity and Structural Changes in Rheumatoid Arthritis Patients Treated with Tocilizumab. Poster 2121. ACR 2012 Annual Scientific Meeting, Washington DC.

Yamaoka K, Kubo S, Sonomoto K, Hirata S, Cavet G, Bolce R, Rowe M, Chernoff D, Defranoux N, Saito K, Tanaka Y. Correlation of a Multi-Biomarker Disease Activity (Vectra ™ DA) Score with Clinical Disease Activity And Its Components with Radiographic Progression in Rheumatoid Arthritis Patients Treated with Tofacitinib. Poster 2162. ACR 2012 Annual Scientific Meeting, Washington DC.

Lamberth S, Cherkas Y, Brodmerkel C, Currran M. Utility of Vectra™ DA on Assessment of Rheumatoid Arthritis Disease Activity and Golimumab Response: Results of a Pilot Study From a Phase 3 Trial in Patients with Active Rheumatoid Arthritis Despite Methotrexate Therapy. Poster 2165. ACR 2012 Annual Scientific Meeting, Washington DC.

Yamaoka K, Kubo S, Sonomoto K, Hirata S, Voinov A, Rowe M, Cavet G, Saito K, Tanaka Y. A Multi-Biomarker Disease Activity Score (MBDA) Score Measures Rheumatoid Arthritis Disease Activity in Patients Treated with the JAK Inhibitor Tofacitinib. Poster THU0145. EULAR Congress 2012.

Ma MH, Ramanujan S, Cavet G, Haney DJ, Zhao X, Eastman PS, Kingsley GH, Scott DL and Cope AP. Investigation of a Multi-Biomarker Disease Activity (Vectra DA) Signature and Algorithm Score in Rheumatoid Arthritis Patients with Low Disease Activity: The REMIRA Study. Poster 361. ACR 2011 Annual Scientific Meeting, Chicago, IL.

Ma MH, Ramanujan S, Haney DJ, Cavet G, Kingsley GH, Scott DL, Cope AP. Biomarker Signatures in Rheumatoid Arthritis Patients with Low Disease Activity: The REMIRA Study. (Poster Session III: May 28, 2011, 10:15 BST). EULAR Congress 2011.

Fleischmann R, Curtis JR, Hamburger M, Blumstein H, Swan K, Cavet G, Chernoff D on behalf of the InFoRM Study Group. RA Population Characteristics in InFoRM: a Longitudinal Observational Study. Poster # SAT0518. EULAR Congress 2010.